Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02003209 · ClinicalTrials.gov registry record · Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 315
- Enrollment target
NCT02003209: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT02003209 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 315 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02003209, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 315 participants
- Enrollment target
Study Summary
This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen deprivation in treating patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer that is operable or has spread from where it started to nearby tissue or lymph nodes (locally advanced). Drugs used in chemotherapy, such as docetaxel, carboplatin, trastuzumab, and pertuzumab, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Estrogen can cause the growth of breast cancer cells. Hormone therapy using goserelin acetate and aromatase inhibition therapy may fight breast cancer by blocking the use of estrogen by the tumor cells. Radiation therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy and radiation therapy with or without hormone therapy may be an effective treatment for hormone receptor-positive, HER2-positive, operable or locally advanced breast cancer.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- OTHER Cytology Specimen Collection Procedure
- DRUG Goserelin Acetate
- DRUG Aromatase Inhibition Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2014-02-18 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02003209
The ClinicalTrials.gov registry entry for NCT02003209 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02003209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02003209 about?
NCT02003209 is a clinical study titled "Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer". This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen deprivation in treating patients with hormone receptor-positive, human epidermal...
What is the current status of trial NCT02003209?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2014-02-18. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT02003209?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Cytology Specimen Collection Procedure (OTHER), Goserelin Acetate (DRUG), Aromatase Inhibition Therapy (DRUG).
Who is sponsoring clinical trial NCT02003209?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.